China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
1.860
-0.120 (-6.06%)
At close: Sep 15, 2025, 4:00 PM EDT
1.790
-0.070 (-3.75%)
After-hours: Sep 15, 2025, 7:34 PM EDT
China SXT Pharmaceuticals Employees
China SXT Pharmaceuticals had 75 employees as of March 31, 2025. The number of employees did not change compared to the previous year.
Employees
75
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$23,212
Profits / Employee
-$44,049
Market Cap
215.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 75 | 0 | - |
| Mar 31, 2024 | 75 | -3 | -3.85% |
| Mar 31, 2023 | 78 | -10 | -11.36% |
| Mar 31, 2022 | 88 | -8 | -8.33% |
| Mar 31, 2021 | 96 | -1 | -1.03% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SXTC News
- 6 months ago - China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency - GlobeNewsWire
- 7 months ago - China SXT Pharmaceuticals, Inc. Announces Share Consolidation - GlobeNewsWire
- 1 year ago - China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule - GlobeNewsWire
- 2 years ago - China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split - GlobeNewsWire
- 3 years ago - China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split - GlobeNewsWire
- 3 years ago - China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million - GlobeNewsWire
- 3 years ago - Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). - Accesswire